Eli Lilly and Company $LLY Stake Lessened by Castleview Partners LLC

Castleview Partners LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 54.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 412 shares of the company’s stock after selling 497 shares during the period. Castleview Partners LLC’s holdings in Eli Lilly and Company were worth $477,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. BlackRock Inc. raised its position in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp boosted its position in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE purchased a new stake in Eli Lilly and Company in the second quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC raised its holdings in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LLY. TD Cowen reissued a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research note on Thursday. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada boosted their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound produced broader biological effects than Taltz alone in adults with psoriasis and obesity. By Week 36, the combination changed 482 proteins versus 140 with Taltz alone and affected 467 genes versus 16, alongside improved skin clearance and weight loss. The findings could strengthen Lilly’s case for treating interconnected metabolic and inflammatory conditions. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Analyst Cantor Fitzgerald raised its Eli Lilly price target to $1,440 from $1,410 and maintained an Overweight rating, implying meaningful upside based on continued obesity-drug demand and pipeline execution. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Recent coverage continues to highlight strong Zepbound demand, potential retatrutide and Foundayo catalysts, and expansion in oncology and Alzheimer’s research. Lilly’s second-quarter revenue growth of roughly 48% and raised outlook provide fundamental support for the long-term growth narrative.
• Neutral Sentiment: Despite its growth profile, Lilly trades below its historical average forward earnings multiple. That may indicate a valuation opportunity, but it also reflects investor concerns about competition, pricing pressure and whether the company’s exceptional growth can continue.
• Neutral Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative may improve future research productivity, although it is unlikely to materially affect near-term earnings. Nvidia and Eli Lilly AI drug-discovery lab
• Negative Sentiment: Lilly’s largest shareholder filed to sell approximately $347 million of stock. The transaction may be routine portfolio management, but its size can raise concerns about insider or major-holder confidence and create additional supply.
• Negative Sentiment: The company is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. Litigation creates regulatory, legal and reputational risk, although the financial impact remains uncertain.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 0.7%

Eli Lilly and Company stock opened at $1,177.57 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The business’s fifty day simple moving average is $1,174.35 and its two-hundred day simple moving average is $1,097.02. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65. The company has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 39.52, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 36.64 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.